Focused on developing next generation antibody drug conjugates (ADCs) and multi-specific antibody-based therapeutics for cancer therapy. The company’s discovery and development efforts are driven by its scalable cell-free protein expression platform (Xpress CF) that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro has three wholly-owned ADCs that are on clinical pathways and three high value collaborations with BMS, Merck, and EMD Serono. STRO-001, anti-CD74 ADC, for multiple myeloma and lymphomas is in Phase 1 and showed encouraging initial safety data at EHA 2019. STRO-002 for ovarian and endometrial cancer is also in a Phase 1 trial. At the AACR-NCI-EORTC conference in October 2019, STRO-002 data showed it was well tolerated and demonstrated early anti-tumor activity in patients with advanced R&R ovarian cancer. Additional Phase 1 dose escalation data for both programs are expected in 2020.
US - Pacific
Phase l or ll
100MM - 500MM
Antibodies, Platform Technology
310 Utah Ave
South San Francisco, CA 94080
Top 10 Holders of Sutro Biopharma, Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by